The Proton Pump Inhibitor Omeprazole Does Not Promote Clostridioides difficile Colonization in a Murine Model

Sarah Tomkovich1, Nicholas A Lesniak1, Yuan Li1

  • 1Department of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA.

Msphere
|November 22, 2019
PubMed

Insights

Proton pump inhibitors (PPIs) like omeprazole did not increase Clostridioides difficile colonization in mice. Omeprazole alone did not disrupt gut microbiota resistance, suggesting other factors may influence PPI-associated CDI risk in humans.

Area of Science:

  • Microbiology
  • Gastroenterology
  • Pharmacology

Background:

  • Proton pump inhibitor (PPI) use is linked to increased risk of Clostridioides difficile infections (CDIs) in humans.
  • PPIs may alter the gut microbiota, potentially reducing resistance to CDI.
  • The exact mechanisms underlying the association between PPIs and CDI remain unclear.

Purpose of the Study:

  • To investigate the impact of omeprazole, a PPI, on the murine fecal microbiota.
  • To determine if omeprazole treatment alone or combined with clindamycin affects susceptibility to Clostridioides difficile colonization in mice.

Main Methods:

  • Mice were treated with omeprazole (40 mg/kg) for 16 days, including a 7-day pretreatment.
  • Some groups received concurrent or sequential clindamycin treatment.
  • Fecal microbiota structure was analyzed using 16S rRNA gene sequencing.

Main Results:

  • Omeprazole treatment alone did not lead to Clostridioides difficile colonization in mice.
  • Combined omeprazole and clindamycin treatment showed variable resistance to colonization.
  • Omeprazole exhibited minimal impact on the overall structure of the murine fecal microbiota.

Conclusions:

  • Omeprazole monotherapy does not disrupt the gut microbiota's resistance to Clostridioides difficile in this mouse model.
  • The findings suggest that factors beyond PPI-induced microbiota changes may contribute to the human association between PPIs and CDI.
  • Further research is needed to elucidate the complex relationship between PPIs, microbiota, and CDI.

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
789
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.0K
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
587
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
862
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
387
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
388